Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies

NANot yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 25, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Solid Tumor, AdultCytotoxicity
Interventions
BIOLOGICAL

Lactobacillus and Bifidobacterium

"Each lot of Lactobacillus and Bifidobacterium and placebo capsules to be used in this study will undergo bioburden testing (tested as per USP \<61\>) to ensure that each lot has:~* Not more than 2000 colony forming unit (CFU) of contaminating (other than the seven strains of bacteria used in the Lactobacillus and Bifidobacterium capsules) aerobic bacteria per gram or dose (whichever is greater);~* Not more than 200 CFU of yeasts and molds per gram or dose (whichever is greater); and~* No bile-tolerant Gram-negative bacteria, Escherichia coli, Salmonella species (in 10 gm), Pseudomonas aeruginosa, Staphylococcus aureus, and Clostridium species per gram or dose (whichever is greater; tested as per USP\<62\>)."

OTHER

Placebo

Placebo capsule manufactured in same facility as experimental capsule.

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT06772090 - Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies | Biotech Hunter | Biotech Hunter